[Primary liver cancer and hepatitis B infection in Senegal. Comparison of cancer patients with 2 control groups].
A case/control study has been carried out to determine the prevalence of hepatitis B surface antigen (HBsAg) and antibody (anti-HBs) in patients with primary liver cancer (PLC), and age/sex matched hospital controls with cancers of other sites (OCC) and similarly matched controls without cancer (NCC). HBsAg was found in 61.2% of 165 cases of PLC, as compared to 11.7% of 154 OCC and 11.3% of 328 NCC. The frequency of HBsAg in PLC patients was significantly higher (72.2%) in those with detectable alpha-fetoprotein as compared to those without (40.3%).
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D005260:Female; D005326:Fetal Proteins / Q000032:analysis*; D006511:Hepatitis B Antigens / Q000032:analysis*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood; D000509:alpha-Fetoproteins / Q000032:analysis*
D005326:Fetal Proteins; D006511:Hepatitis B Antigens; D000509:alpha-Fetoproteins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin
Cancer primitif du foie et infection par l'hépatite B au Sénégal. Comparaison des sujets cancéreux avec deux groupes témoins